Drs. Chandwani and Kuruvilla explain that migraine and facial pain often share trigeminal system mechanisms, leading to frequent misdiagnosis as dental, musculoskeletal, or sinus problems, possibly resulting in unnecessary procedures. The speakers emphasize CGRP-targeted therapies, careful mechanism-based diagnosis, and multidisciplinary collaboration across neurology, orofacial pain, physical therapy, and behavioral health to improve outcomes for patients with complex facial pain and migraine presentations.

Drs. Wierda and O’Brien discuss new combination treatments for CLL that achieve exceptionally high rates of undetectable disease, especially with triplet regimens. They also show that venetoclax-based retreatment works very well, supporting a move away from chemoimmunotherapy.

Drs. Yiu and Emami continue their wrap-up of the highlights from the 49th Annual Macula Society Meeting, focusing on new developments in imaging technologies, AI, and drug delivery for retinal diseases. They also touch on emerging basic science topics like the gut microbiome and metabolomics, and how these may support more personalized, systems-level approaches to eye disease.

Drs. Mantia and Berg continue their discussion of ESMO 2025 data on HER2‑directed antibody–drug conjugates in urothelial cancer and the importance of routine HER2 testing. They highlight the promising efficacy and manageable toxicity of these agents across disease stages and raise future questions about how best to sequence them.

This episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.

Drs. Sarswat and Dasgupta discuss contemporary decision-making in treating transthyretin amyloidosis, comparing oral stabilizers with subcutaneous silencers and emphasizing earlier diagnosis, phenotype-driven therapy, and individual patient preferences. They highlight how neuropathy and autonomic dysfunction influence choice of mechanism, review practical considerations such as side-effect profiles, dosing logistics, and drug–drug interactions, and briefly touch on emerging approaches like amyloid-removing and gene-targeted therapies.

Drs. Maron and Rowin focus on modern treatment options for patients with symptomatic obstructive hypertrophic cardiomyopathy, including both new medications and long-established invasive procedures that relieve heart obstruction and improve symptoms. They emphasize that multiple effective choices now exist, and that factors like patient preference, access to drugs, and other heart conditions help determine the best approach.

New evidence from JAMA Network Open suggesting that switching direct oral anticoagulants after breakthrough ischemic stroke in atrial fibrillation does not improve short-term outcomes; NEJM data from the Beamion LUNG-1 trial showing promising first-line efficacy of zongertinib in HER2-mutant NSCLC; and 10-year follow-up from the FIDELITY trial reinforcing that arthroscopic partial meniscectomy offers no benefit over sham surgery for degenerative meniscal tears and may worsen osteoarthritis progression. Together, these findings may influence future standards in stroke prevention, targeted lung cancer therapy, and orthopedic surgical decision-making.

Drs. Sanossian and Saver highlight emerging evidence that routine dental care and oral hygiene may function as actionable, modifiable contributors to stroke prevention beyond traditional vascular risk factors. They also review CREST-2 data showing that carotid revascularization in asymptomatic high-grade carotid stenosis reduces stroke risk, but does not appear to confer additional cognitive benefit over intensive medical therapy alone.

Drs. Swigris and Humphries discuss how data-driven texture analysis (DTA) on HRCT enables precise, objective quantification of fibrotic burden in ILD, overcoming the limitations of semi-quantitative visual scoring and blunt physiologic measures. They further describe a complementary AI-based classifier that predicts histologic usual interstitial pneumonia (UIP) patterns from CT, enhancing prognostication and potentially reducing the need for surgical lung biopsy.